HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.
What happened
FDA inspected HTO Nevada dba Kirkman's drug manufacturing facility in Lake Oswego, OR, from August 18 to 22, 2025. FDA found that the quality unit released reformulated OTC drugs with labels still showing the previous active ingredient, and that the firm lacked process validation data and an adequate stability program. FDA said the firm's September 12, 2025 response was inadequate and noted similar observations from a 2019 inspection.
What FDA found
The quality unit did not ensure change control, so reformulated OTC drugs were released and distributed with labels that still listed the old active ingredient.
21 CFR 211.22(d)The quality unit did not adequately oversee contract testing laboratories, including their qualification, method validation, and written agreements.
21 CFR 211.22(a) and 211.22(b)The quality unit did not perform periodic production reviews at least annually.
21 CFR 211.180(e)The firm lacked process validation data and adequate written production and process control procedures, and it failed to adequately qualify and test a system used in manufacturing.
21 CFR 211.100(a)The firm failed to establish and follow an adequate written stability testing program; its stability protocol was an incomplete 24-month report without recorded results or appropriate signatures.
21 CFR 211.166(a)
What FDA wants
FDA asks the firm to respond in writing within 15 working days with corrective actions and risk assessments for the API change, distributed products made without process validation, the manufacturing system failures, and the stability program. FDA also asks the firm to clarify whether it will resume drug manufacturing and to notify FDA before resuming.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- distributors and retailers selling Kirkman OTC drug products
- quality teams managing supplier qualification, change control, and labeling
This is a summary. Read the original letter on fda.gov.